Introduction
============

As the resistance of pathogenic bacteria to conventional antibiotics is on the rise, new sources of antibiotics are being sought including cationic antimicrobial peptides and polymyxins (Hancock and Sahl, [@B35]). These compounds are naturally occurring and are produced by most forms of life from microbes to mammals (Yeaman and Yount, [@B89]). They can act as antibiotics against bacteria but also have a wide range of important immunomodulatory activities *in vivo* (Lai and Gallo, [@B48]). Antimicrobial peptides represent a potential new source of antibiotics for treatment of various bacterial infections, including opportunistic infections in cystic fibrosis (CF) patients (Zhang et al., [@B91]), and are being used to as a last resort to treat some infections by multidrug resistant bacteria (Zavascki et al., [@B90]). Antimicrobial peptides cause disruption of the cytoplasmic membrane of bacteria (inner membrane in Gram-negative bacteria), but can also inhibit intracellular processes such as nucleic acid, DNA, or protein synthesis (Brogden, [@B5]). Resistance mechanisms have been characterized in various Gram-negative bacteria, including *Escherichia coli*, *Salmonella enterica*, and *Pseudomonas aeruginosa*. Many resistance mechanisms in Gram-negative bacteria involve alterations of the lipopolysaccharide (LPS) molecule of the outer membrane, which reduce the access of antimicrobial peptides and polymyxins to the inner membrane (Vaara et al., [@B80]; Gunn et al., [@B29]; Guo et al., [@B32]; Tamayo et al., [@B77]). Many Gram-positive bacteria display analogous alterations to their lipoteichoic and wall teichoic acids resulting in reduced access of these compounds to their cytoplasmic membranes (Peschel et al., [@B64]; Kovács et al., [@B45]; Giaouris et al., [@B24]).

A group of extremely antimicrobial peptide resistant Gram-negative bacteria exist and the best characterized of these organisms are species of the genus *Burkholderia*. This review summarizes the current state of knowledge concerning antimicrobial peptide and polymyxin resistance among the *Burkholderia* and discusses how the treatment of infections caused by sensitive bacteria with antimicrobial peptides or polymyxins could impact infections by resistant Gram-negative bacteria.

The Genus *Burkholderia*: Pathogens Amongst the Weeds
=====================================================

The genus *Burkholderia* comprises over 40 species of bacteria, most of which have been isolated from soil or fresh water. Members of this genus are symbionts of plants, fungi, and insects and pathogens of plants, fungi, and non-human mammals (for an excellent review on the distribution of *Burkholderia* bacteria within the environment see Compant et al., [@B12]). Within this genus are a group of at least 17 species, collectively known as the *Burkholderia cepacia* complex, that cause chronic opportunistic infections particularly in patients with CF or chronic granulomatous disease (Mahenthiralingam et al., [@B55]; Vanlaere et al., [@B82]). The genus also includes two species that cause acute infections in humans: *B. pseudomallei*, the causative agent of melioidosis (Cheng and Currie, [@B10]), and *B. mallei*, a facultative intracellular bacterium that causes glanders (Gregory et al., [@B26]). Acute and opportunistic infections by other members of the genus have also been reported (Gerrits et al., [@B23]; Sudo et al., [@B76]; Glass et al., [@B25]; Weinberg et al., [@B86]; Lestin et al., [@B49]; Deris et al., [@B15]).

Within the natural environment abundant opportunities arise during which *Burkholderia* bacteria may be exposed to antimicrobial peptides, polymyxins, and other similar compounds; this exposure is likely to have contributed a selective pressure for the evolution of high levels of resistance in these organisms. The rhizosphere is home to many microorganisms that produce antibiotics and many antibiotics have been directly detected from rhizosphere soil (Berg et al., [@B3]). These include bacteria such as *Paenibacillus polymyxa*, which contains the genetic material required to make polymyxins, a lantibiotic, bacitracin, and other antibiotics (Ma et al., [@B54]). *Burkholderia* sp. also form symbiotic and/or pathogenic interactions with insects and plants (Compant et al., [@B12]). These hosts also produce antimicrobial peptides (García-Olmedo et al., [@B22]; Bulet and Stocklin, [@B6]) which *Burkholderia* bacteria are likely exposed to at some point in their symbiosis or pathogenesis.

Antimicrobial Peptide and Polymyxin Resistance in the Genus *Burkholderia*
==========================================================================

Members of the genus *Burkholderia* are inherently resistant to many antimicrobial agents (Mahenthiralingam et al., [@B55]); they have been shown to grow on penicillin as a sole carbon source (Vermis et al., [@B83]) and survive in solutions of chlorhexidine used for disinfection of hospital equipment (Heo et al., [@B37]). For the purpose of this review we considered Gram-negative bacteria to be extremely resistant to antimicrobial peptides and polymyxins if minimum inhibitory concentration (MIC) values of 500 μg/ml or more have been reported. Numerous species of *Burkholderia* bacteria fall into this category (Table [1](#T1){ref-type="table"}). For comparison, reported MIC values for sensitive Gram-negative bacteria such as *E*. *coli*, *S*. *enterica*, and *P*. *aeruginosa* are several orders of magnitude lower than those for *Burkholderia* sp. (Table [1](#T1){ref-type="table"}).

###### 

**Antimicrobial peptide and polymyxin resistance values for many of the studies discussed in the text**.

  Species/strain                       Assay                       Compound                     Value               References
  ------------------------------------ --------------------------- ---------------------------- ------------------- --------------------------------
  *B. pseudomallei* 1026b              MIC                         Polymyxin B                  128 mg/ml           Burtnick and Woods ([@B7])
                                                                   Colistin                     128 mg/ml           
  *B. cepacia* ATCC 17770              MIC                         Human β-defensin-3           6.6 μg/ml           García et al. ([@B21])
  *B. vietnamiensis* (11/11 strains)   MIC                         Bactenecin 2a                \> 128 μg/ml        Jassem et al. ([@B41])
                                                                   LL-37                        \> 128 μg/ml        
  *B. vietnamiensis* (10/11 strains)   MIC                         Polymyxin B                  \> 75 μg/ml         
  *B. vietnamiensis* FC0656            MIC                         Polymyxin B                  37.5 μg/ml          
                                       MIC~50~                     Polymyxin B                  \> 1024 μg/ml       Loutet et al. ([@B52], [@B51])
                                                                   Melittin                     \> 512 μg/ml        
  *B. cenocepacia* K56-2               Inhibition on solid media   Human neutrophil peptide-1   \> 100 μg/ml        
  *B. cenocepacia* J2315               MIC~50~                     Polymyxin B                  \> 512 μg/ml        
  18 Strains from five species:        MIC~50~                     Polymyxin B                  \> 256 μg/ml        Thwaite et al. ([@B78])
  *B. cepacia*                                                     Calcitermin                  \> 256 μg/ml        
  *B. multivorans*                                                 Cecropin A                   \> 256 μg/ml        
  *B. cenocepacia*                                                 Granulysin                   \> 256 μg/ml        
  *B. stabilis*                                                    LL-37                        \> 256 μg/ml        
  *B. vietnamiensis*                                               MUC-7                        \> 256 μg/ml        
                                                                   P113                         \> 256 μg/ml        
                                                                   Ovine polyaspartic acid      \> 256 μg/ml        
                                                                   Magainin II                  8 to \> 256 μg/ml   
  *S. enterica* (Typhimurium) 1408s    MIC                         Polymyxin B                  1.9 μg/ml           Gunn et al. ([@B29])
  *P. aeruginosa* H103                 MIC                         Polymyxin B                  8 μg/ml             McPhee et al. ([@B56])
  *E. coli* SC9251                     MIC                         Polymyxin B                  0.5 μg/ml           Vaara and Vaara ([@B79])

Antimicrobial peptide and polymyxin resistance has been investigated in various different *Burkholderia* sp. and a variety of major and minor determinants of antimicrobial peptide and polymyxin resistance have been proposed for members of the genus *Burkholderia* (Figure [1](#F1){ref-type="fig"}). An early study in *B. cepacia* (formerly *Pseudomonas cepacia*) showed that unlike *P. aeruginosa*, polymyxin B bound poorly to whole cells of *B. cepacia* and was unable to permeabilize the outer membrane of *B. cepacia* to a second molecule (1-*N*-phenylnaphthylamine; Moore and Hancock, [@B57]); these observations have since been confirmed in *B. cenocepacia* and *B. pseudomallei* (Burtnick and Woods, [@B7]; Ortega et al., [@B61]). These initial stages in the action of polymyxin B are known as the self-promoted uptake pathway, a process by which a cationic antibiotic displaces divalent cations that bridge LPS molecules and promote the uptake of other molecules across the outer membrane by decreasing the permeability of the membrane (Hancock and Wong, [@B34]). Moore and Hancock ([@B57]) concluded that unique properties of the *B. cepacia* outer membrane blocked the self-promoted uptake of polymyxin B and that this explained, at least in part, the high levels of resistance seen in the organism.

![**Proposed antimicrobial peptide and/or polymyxin resistance mechanisms in *Burkholderia* species**. The model depicts LPS as providing a major barrier to binding of peptides (Loutet et al., [@B53]) and the possible role of the metalloproteases ZmpA and ZmpB in degrading antimicrobial peptides. The periplasmic protein involved in resistance by an unknown mechanism is MucD, which is homologous to members of the HtrA protease family. In our model, IspH, an enzyme involved in the synthesis of isoprenoids could play a role in antimicrobial peptide resistance by introducing modifications of the lipid composition of the inner membrane, while the efflux pump NorM could mediate the efflux of peptides that cross the inner membrane and gain access to the cytoplasm. The regulators RpoE and BCAL2831 participate in global regulatory responses leading to an increase in antimicrobial peptide resistance. The genes regulated by RpoE and BCAL2831 and involved in these responses have not been identified, but it is likely RpoE regulates mucD since the genes encoding both proteins are co-transcribed (Flannagan and Valvano, [@B19]).](fcimb-01-00006-g001){#F1}

Burtnick and Woods ([@B7]) used a random screen to identify determinants of antimicrobial peptide resistance in *B. pseudomallei*. These authors reported that *B. pseudomallei* had the ability to grow in concentrations of polymyxin B as high at 128 mg/ml and obtained polymyxin B-sensitive transposon mutants in three genes. One gene (*waaF*) encodes a protein required for LPS core oligosaccharide biosynthesis. The others encoded a predicted enzyme with UDP-glucose dehydrogenase activity and an enzyme called IspH (formerly LytB), which at the time was thought to be involved in the bacterial stringent response (Gustafson et al., [@B33]) but has since been shown to be required for the synthesis of isoprenoids (Rohdich et al., [@B67]). All of these pathways are also involved in antimicrobial peptide and polymyxin resistance in *B. cenocepacia* (Loutet et al., [@B52], [@B51], [@B53]; Ortega et al., [@B61]).

In numerous Gram-negative bacteria, the sugar 4-amino-4-deoxy-[l]{.smallcaps}-arabinose (Ara4N) is synthesized and then added to the lipid A component of LPS to increase antimicrobial peptide and polymyxin resistance (Nummila et al., [@B60]; Gunn et al., [@B29]; Ernst et al., [@B17]; Winfield et al., [@B87]). However, in most Gram-negative bacteria synthesis of this sugar is dispensable under most growth conditions and the sugar is not normally found in the lipid A molecule. Many studies have shown that *Burkholderia* sp. produce Ara4N constitutively as part of their LPS molecule, in some cases placing the sugar in both the lipid A and core oligosaccharide portions of the molecules (Isshiki et al., [@B40]; Gronow et al., [@B27]; Silipo et al., [@B69], [@B70]; Brett et al., [@B4]; Novem et al., [@B59]; Ortega et al., [@B61]). The constitutive presence of this sugar in the LPS molecule was suggested to be a major determinant of antimicrobial peptide resistance in *Burkholderia* sp. (Cox and Wilkinson, [@B13]; Vinion-Dubiel and Goldberg, [@B84]). Initial attempts in our laboratory to disrupt the genes required for the synthesis of Ara4N in *B. cenocepacia* failed, which led to the hypothesis that this sugar was essential for *B. cenocepacia* viability. Ortega et al. ([@B62]) constructed conditional mutants in this pathway and showed that both the synthesis of Ara4N and the transfer of Ara4N to lipid A are essential. Depletion of proteins from this pathway in conditional mutants resulted in morphological changes such as accumulation of membranous material inside the cell, empty sacculi, and division septa defects, decreased viability as measured by live/dead staining, and increased sensitivity to detergents (Ortega et al., [@B62]). The morphological changes are reminiscent of those observed in mutants of the essential Lpt pathway, responsible for the translocation of LPS from the inner membrane to the outer membrane (Sperandeo et al., [@B71], [@B72]). The first step in the synthesis of Ara4N is the conversion of UDP-glucose to UDP-glucuronic acid, a reaction catalyzed by the protein UDP-glucose dehydrogenase (Ugd; Raetz and Whitfield, [@B65]). Loutet et al. ([@B51]) showed that the combination of two *ugd* genes, *ugd~BCAL2946~* and *ugd~BCAM0855~*, is essential for the viability of *B. cenocepacia*, while the most highly expressed gene, *ugd~BCAL2946~*, is required for polymyxin B resistance. As a component of the Ara4N synthesis pathway, *ugd* genes have often been implicated in antimicrobial peptide resistance in other organisms (Burtnick and Woods, [@B7]; Mouslim and Groisman, [@B58]; Hung et al., [@B39]). Although this study links a gene in the Ara4N synthesis pathway with a predicted role in polymyxin B resistance, the content of Ara4N in the LPS molecule of this mutant has not yet been determined (Loutet et al., [@B51]). To date it has not been possible to assess the precise contribution of Ara4N to antimicrobial peptide resistance in *B. cenocepacia* because due to their essential nature no mutant strain completely lacking Ara4N in the LPS molecule has been reported in the literature.

A second region of the LPS molecule, the core oligosaccharide, also contributes to antimicrobial peptide resistance in *B. cenocepacia*. Progressive truncation of the LPS core oligosaccharide results in increasing sensitivity of *B. cenocepacia* to polymyxin B and increasing binding of polymyxin B to whole cells (Ortega et al., [@B61]). A severe LPS core oligosaccharide truncation leads to the loss of the sugar [l]{.smallcaps}-*glycero*-[d]{.smallcaps}-*manno*-heptose and all sugars added after these residues. This "deep-rough" truncation typically causes pleiotropic effects in Gram-negative bacteria (Raetz and Whitfield, [@B65]; Valvano et al., [@B81]). A heptoseless LPS mutant of *B*. *cenocepacia* displayed increased sensitivity to numerous antimicrobial agents, and in particular to polymyxin B and to structurally unrelated antimicrobial peptides such as melittin and human neutrophil peptide-1 (Loutet et al., [@B52]). The mutant strain used in this study was unable to synthesize [l]{.smallcaps}-*glycero*-[d]{.smallcaps}-*manno*-heptose and these results were later confirmed in a *B. cenocepacia* mutant strain able to synthesize this sugar but unable to transfer it to the LPS molecule (Ortega et al., [@B61]).

The other major determinant of resistance described in *B. cenocepacia* is the alternative sigma factor RpoE (Loutet et al., [@B53]). This alternative sigma factor controls the expression of a regulon of genes that encode proteins required for bacteria to respond to extracytoplasmic stress (Raina et al., [@B66]). In *B. cenocepacia*, RpoE plays a significant role in polymyxin B resistance (but not melittin resistance; Loutet et al., [@B53]). It is also required for polymyxin B resistance at 37°C but not at 30°C (Flannagan and Valvano, [@B19]; Loutet et al., [@B53]). These results support the notion that an extremely resistant organism can have resistance determinants that are required for some compounds but not others and only under certain conditions.

Three studies have proposed additional minor determinants of antimicrobial peptide resistance in *Burkholderia* sp. First, Fehlner-Gardiner and Valvano ([@B18]) demonstrated that in *B. vietnamiensis*, NorM, a member of the multidrug and toxic compound extrusion family of efflux systems (Kuroda and Tsuchiya, [@B47]), contributed to polymyxin B resistance, but only in the presence of exogenously added tetracycline. In the absence of tetracycline, the efflux pump played little part in polymyxin B resistance. Second, Kooi and Sokol ([@B44]) demonstrated that two secreted zinc metalloproteases of *B. cenocepacia* (ZmpA and ZmpB) could degrade various antimicrobial peptides *in vitro* but that *B. cenocepacia* mutant strains lacking either ZmpA, ZmpB, or both did not exhibit increases in susceptibility to antimicrobial peptides other than a small increase in mutants lacking ZmpB to protamine. Third, we recently demonstrated that determinants of antimicrobial peptide resistance could be identified in a deep-rough LPS *B. cenocepacia* mutant (which lacks one of the major determinants of antimicrobial peptide resistance). These determinants, which included a two-component response regulator (BCAL2831), a periplasmic protease (MucD), and one of two IspH proteins, play little or no detectable role in a strain with its LPS molecule intact (Loutet et al., [@B53]).

Together, these studies provide evidence that extreme resistance of *Burkholderia* sp. to antimicrobial peptides is likely multifactorial (Figure [1](#F1){ref-type="fig"}) and consists of major and minor determinants of resistance. This led us to propose a two-tier model of antimicrobial peptide resistance in *B. cenocepacia* (Loutet et al., [@B53]). In the first tier of this model, we hypothesize that the outer membrane impermeability barrier and poor peptide binding maintained, at least in part, by unique aspects of the LPS molecule provides the majority of the resistance seen in this organism in conjunction with major peptide- or condition-specific resistance mechanisms (such as the requirement for RpoE for polymyxin B resistance at 37°C). In the second tier of the model, we have proposed that various other resistance mechanisms exist, each playing a small role in resistance but as a whole contributing substantially to the high total resistance of the organism. These mechanisms may be difficult to identify experimentally in the presence of the strong outer membrane impermeability barrier and poor peptide binding mediated by LPS.

There are Exceptions to Every Rule
==================================

Of course, there are exceptions to the idea that *Burkholderia* bacteria are universally resistant to antimicrobial peptides and polymyxins (Table [1](#T1){ref-type="table"}). In a study using numerous isolates (both clinical and environmental) of *B. vietnamiensis*, Jassem et al. ([@B41]) found that while a large majority of the isolates were resistant to all of the peptides tested, the growth of one environmental isolate (strain FC0656) was inhibited by 37.5 μg/ml of polymyxin B. Thwaite et al. ([@B78]) found that of eight antimicrobial peptides tested, seven failed to inhibit the growth of five different *Burkholderia* sp. at up to 256 μg/ml of antimicrobial peptide. However one, magainin II, could inhibit the growth of many different *Burkholderia* strains at concentrations ranging from as low as 8 to 256 μg/ml. Additionally, the growth of one strain of *B. cepacia* was inhibited by a relatively low concentration (6.6 μg/ml) of human β-defensin-3 (García et al., [@B21]).

Emerging Opportunists may be Extremely Resistant to Antimicrobial Peptides
==========================================================================

There is evidence that various emerging opportunistic pathogens may be extremely resistant to antimicrobial peptides. Coenye et al. ([@B11]) analyzed a collection of unusual bacteria isolated from CF patients and misidentified at hospitals as members of the Bcc. The authors of this study found various different isolates, most of which had never or only very rarely been reported as isolated from CF patients. One reason many of these isolates were misidentified as members of the Bcc was their ability to grow on *B. cepacia* selective agar (BCSA), a media formulated for the selection of members of the Bcc. BCSA contains approximately 100 μg/ml of polymyxin B, which typically allows for the selective isolation of Bcc bacteria from other opportunistic pathogens of CF patients (Henry et al., [@B36]). Non-Bcc isolates from CF patients that were able to grow on BCSA included *Ralstonia mannitolilytica*, *R. gilardii*, *Pandoraea* sp., *Acinetobacter baumannii*, *Chromobacterium violaceum*, *P. huttiensis*, *Xanthomonas hyacinthi*, and *Inquilinus limosus* (Coenye et al., [@B11]). Since this study, a second report detailed pulmonary infections in 28 CF patients with *Herbaspirillum* sp., most of which also grew on BCSA and were misidentified as Bcc bacteria (Spilker et al., [@B73]). These results show that various organisms, phenotypically similar to *B. cenocepacia* and resistant to polymyxin B, have the ability to infect patients with CF. Finally, treatment of susceptible *P. aeruginosa* (MIC values between 1.6 and 6.1 μg/ml) infections in CF patients with colistin (polymyxin E) has lead to the isolation of colistin-resistant *P. aeruginosa* isolates (MIC values between 100 and 400 μg/ml; Johansen et al., [@B42]).

Future Directions of Study
==========================

There are multiple experimental lines to continue in the investigation of antimicrobial peptide and polymyxin resistance in *Burkholderia* sp. It is important to determine if *Burkholderia* bacteria make a transcriptional response to antimicrobial peptides. Since two regulatory systems, RpoE and a two-component system (BCAL2830/BCAL2831), have been implicated in the resistance of *B. cenocepacia* (Loutet et al., [@B53]) it seems likely that some transcriptional response occurs upon exposure to antimicrobial peptides. Genes whose transcription change upon treatment with antimicrobial peptides, as well as those controlled by RpoE and BCAL2830/BCAL2831, could prove to be important players in resistance and provide additional insight into mechanisms of resistance in these bacteria. The genes regulated by RpoE and BCAL2830/BCAL2831 have not been identified, though *mucD* is likely regulated by RpoE, since it is in the *rpoE* operon (Flannagan and Valvano, [@B19]), in other organisms *rpoE* gene expression is autoregulated (Raina et al., [@B66]), and preliminary experiments suggest that this is also the case in *B. cenocepacia* (El-Halfawy and Valvano, unpublished).

Understanding the essential nature of Ara4N substitutions of the LPS molecule in *Burkholderia* will likely provide significant insight into the unique properties of the outer membrane of these bacteria that set them apart from other Gram-negative bacteria. Compounds to disrupt the Ara4N pathway are being developed as potential therapeutics to administer with antimicrobial peptides or polymyxins (Kline et al., [@B43]). Such compounds might be very powerful anti-*Burkholderia* agents due to the essential nature of this pathway.

Since so many pathways have been implicated in the resistance of *Burkholderia* to antimicrobial peptides and polymyxins, another avenue to explore that could lead to the development of an anti-*Burkholderia* therapeutic is to identify compounds that synergize with these antibiotics against *Burkholderia*. We have recently begun to test this concept with a small library of naturally occurring compounds derived from marine life and have identified some potential lead molecules that increase polymyxin B sensitivity (Loutet and Valvano, unpublished). Other groups are screening compound libraries to find inhibitors of specific pathways (De Leon et al., [@B14]), such as the synthesis of [l]{.smallcaps}-*glycero*-[d]{.smallcaps}-*manno*-heptose sugars required for the LPS core oligosaccharide of Gram-negative bacteria (Valvano et al., [@B81]) and that have been shown to be required for antimicrobial peptide resistance and *in vivo* survival of *B. cenocepacia* (Loutet et al., [@B52]). All of these avenues of future research could potentially lead to a therapeutic strategy where a patient with a *Burkholderia* infection would receive a therapeutically applied antimicrobial peptide and a second drug that potentiates the activity of the peptide by reducing bacterial resistance to it.

Concluding Remarks
==================

Much progress has been made to identify antimicrobial peptide resistance mechanisms in many different Gram-negative and Gram-positive bacteria (Yeaman and Yount, [@B88]). These resistance mechanisms include: changes to the cytoplasmic membrane in both Gram-negative and Gram-positive bacteria (Dorrer and Teuber, [@B16]; Peschel et al., [@B63]), alterations to teichoic acids in Gram-positive bacteria (Peschel et al., [@B64]) and LPS in Gram-negative bacteria (Vaara et al., [@B80]), efflux pumps (Shafer et al., [@B68]), proteases (Stumpe et al., [@B75]; Guina et al., [@B28]; Caldas et al., [@B8]; Belas et al., [@B1]), exopolysaccharides (Benincasa et al., [@B2]; Foschiatti et al., [@B20]), capsule polysaccharides (Campos et al., [@B9]; Spinosa et al., [@B74]; Llobet et al., [@B50]), modification of intracellular antimicrobial peptide targets (Vizán et al., [@B85]), and the coordination of resistance mechanisms through transcriptional regulation (Gunn and Miller, [@B30]; Guo et al., [@B31]; Humphreys et al., [@B38]; McPhee et al., [@B56]; Winfield et al., [@B87]; Kraus et al., [@B46]).

Members of the genus *Burkholderia* are the best studied among the highly antimicrobial peptide resistant species of Gram-negative bacteria, and a series of major and minor resistance determinants have been proposed for these bacteria (Figure [1](#F1){ref-type="fig"}). Studies in the *Burkholderia* could provide a model for the other extremely resistant Gram-negative bacteria. It is important to understand resistance in these organisms because many of these bacteria are opportunistic human pathogens that establish chronic infections. In this context, using antimicrobial peptides and polymyxins to treat infections by susceptible bacteria (such as *P. aeruginosa* infections in the CF lung) may give rise to subsequent infections by opportunistic pathogens that are resistant to these compounds.
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